abingworth  broad strategic approach signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal broad strategic approach we partner with entrepreneurs to create companies that have a significant impact on patients’ lives participating at all stages of development and across all sectors we take a broad strategic approach to investing in life sciences within this market we participate in a wide range of opportunities spanning therapeutics medical devices diagnostics instrumentation and software we invest in seed stage projects technology platforms preclinical and clinical assets as well as approved and marketed products supporting private and public companies we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare typical investments investment size   m in total per company ownership             majority or minority geography   primarily us and europe holding period    years sectors   biotherapeutics small molecules nucleic acid therapeutics vaccines specialty pharma technologies medical devices diagnostics instrumentation home terms of use privacy policy frc stewardship code copyright abingworth  home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal broad strategic approach we partner with entrepreneurs to create companies that have a significant impact on patients’ lives participating at all stages of development and across all sectors we take a broad strategic approach to investing in life sciences within this market we participate in a wide range of opportunities spanning therapeutics medical devices diagnostics instrumentation and software we invest in seed stage projects technology platforms preclinical and clinical assets as well as approved and marketed products supporting private and public companies we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare typical investments investment size   m in total per company ownership             majority or minority geography   primarily us and europe holding period    years sectors   biotherapeutics small molecules nucleic acid therapeutics vaccines specialty pharma technologies medical devices diagnostics instrumentation   disclaimer privacy policy fpcs code copyright abingworth  abingworth  home signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal collaboratecrispr is an earlystage company created to translate breakthrough geneediting technology into transformative medicines for serious human diseases abingworth is helping crispr to select its first therapeutic indications and build its team innovatenasdaqlisted paratek is developing novel antibiotics to tackle communityacquired infections abingworth helped recruit the team and coled the investment creategammadelta is exploiting the unique properties of tissue resident γδ t cells for effective immunotherapy abingworth has supported and incubated the young uk company since its inception collaborateavillion is a clinical codevelopment company providing funding and operational expertise to accelerate the development of late stage therapeutics abingworth created and incubated the ukbased company innovateabingworth is working with effector to develop a novel class of small molecule drugs that selectively regulate translational control of gene expression the clinical stage company has an initial emphasis on cancer including immunooncology createsutrovax is developing a potential bestinclass conjugate vaccine to prevent invasive pneumococcal disease which can cause pneumonia meningitis and blood stream infections abingworth led the series a financing and helped with the company’s business development and expansion plans latest news  jul  effector therapeutics completes  million series c financing  read more  jul  dr moncef slaoui former glaxosmithkline chairman of vaccines appointed to sutrovax board of directors  read more  jul  paratek announces phase  study of oralonly dosing of omadacycline met all primary and secondary fda and ema efficacy endpoints in acute bacterial skin infections  read more • see all films •   about strategy portfolio media centre contact terms of use privacy policy frcs code copyright abingworth  slides paused slides restarting home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal collaborate crispr is an earlystage company created to translate breakthrough geneediting technology into transformative medicines for serious human diseases abingworth is helping crispr to select its first therapeutic indications and build its team innovate nasdaqlisted paratek is developing novel antibiotics to tackle communityacquired infections abingworth helped recruit the team and led the investment create gammadelta is exploiting the unique  properties of tissue resident γδ t cells for  effective immunotherapy abingworth has  supported and incubated the young uk  company since its inception collaborate avillion is a clinical codevelopment company providing funding and operational expertise to accelerate the development of late stage therapeutics abingworth created and incubated the ukbased company innovate abingworth is working with effector to develop a novel class of small molecule drugs that selectively regulate translational control of gene expression the clinical stage company has an initial emphasis on cancer including immunooncology create sutrovax is developing a potential bestinclass conjugate vaccine to prevent invasive pneumococcal disease which can cause pneumonia meningitis and blood stream infections abingworth led the series a financing and helped with the company’s business development and expansion plans   latest news  jul  effector therapeutics completes  million series c financing  read more  jul  dr moncef slaoui former glaxosmithkline chairman of vaccines appointed to sutrovax board of directors  read more  jul  paratek announces phase  study of oralonly dosing of omadacycline met all primary and secondary fda and ema efficacy endpoints in acute bacterial skin infections  read more • see all films • disclaimer privacy policy fpcs code copyright abingworth  abingworth  our whole team working with you signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal our whole team working with you when we invest in your business you receive support from our whole team our transatlantic group has started many companies and has broad expertise in science medicine strategy and business we can help attract talent for boards and leadership teams choose drug targets for novel platforms devise plans for clinical development navigate legal issues advise on pr strategy and think through corporate development and exit strategies added to our own knowledge we have a wide network of leading scientific and industry experts our collective experience is offered to portfolio companies executive team kurt von emster managing partner menlo park usa tim haines managing partner london uk michael bigham executive partner boston usa stephen bunting chairman london uk shelley chu partner menlo park usa ken haas partner menlo park usa genghis lloydharris partner london uk vincent miles partner boston usa james abell partner  cfo london uk alex asquith counsel london uk john heard partner  general counsel london uk sarah shackelton partner marketing  talent london uk andrew sinclair partner portfolio manager london uk victoria stewart public relations london uk advisors peter goodfellow advisor london uk john shields advisor london uk operations  support natalie andersonsaturley assistant london uk tally badesha it manager london uk david bird fund accountant london uk maryellen craig assistant boston usa howard ng assistant accountant london uk gwen kinard executive assistantoffice manager menlo park usa hannah mullins assistant london uk siew tin yew financial controller london uk lata vyas operations manager london uk filter location london uk menlo park usa boston usa all home terms of use privacy policy frc stewardship code copyright abingworth  home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal our whole team working with you when we invest in your business you receive support from our whole team our transatlantic group has started many companies and has broad expertise in science medicine strategy and business we can help attract talent for boards and leadership teams choose drug targets for novel platforms devise plans for clinical development navigate legal issues advise on pr strategy and think through corporate development and exit strategies added to our own knowledge we have a wide network of leading scientific and industry experts our collective experience is offered to portfolio companies executive team kurt von emster tim haines michael bigham stephen bunting shelley chu ken haas genghis lloydharris vincent miles james abell alex asquith john heard sarah shackelton andrew sinclair victoria stewart advisors peter goodfellow john shields operations  support natalie andersonsaturley tally badesha david bird maryellen craig howard ng gwen kinard hannah mullins siew tin yew lata vyas   disclaimer privacy policy fpcs code copyright abingworth  abingworth   life science funds signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal  life science funds abingworth has raised  funds dedicated to investing in life sciences and healthcare our most recent abingworth clinical codevelopment fund and abingworth bioventures vi raised  million and £ million  million respectively and are actively investing venture funds our venture funds invest across our broad strategic areas of venture capital pharmaceutical codevelopment vipes and public markets they focus primarily on private companies but are able to invest a percentage of their value in public companies public market fund abingworth bioequities abe is dedicated solely to investing in public life science companies employing a longonly investment approach our openended fund invests worldwide in public smallcap life sciences companies taking leadership positions in syndicated deals participating in private placements as well as buying and selling shares in the open market     home terms of use privacy policy frc stewardship code copyright abingworth  home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal  life science funds abingworth has raised  funds dedicated to investing in life sciences and healthcare our most recent abingworth clinical codevelopment fund and abingworth bioventures vi raised  million and £ million  million respectively and are actively investing venture funds our venture funds invest across our broad strategic areas of venture capital pharmaceutical codevelopment vipes and public markets they focus primarily on private companies but are able to invest a percentage of their value in public companies public market fund abingworth bioequities abe is dedicated solely to investing in public life science companies employing a longonly investment approach our openended fund invests worldwide in public smallcap life sciences companies taking leadership positions in syndicated deals participating in private placements as well as buying and selling shares in the open market       disclaimer privacy policy fpcs code copyright abingworth  abingworth  public markets signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal abingworth became a significant investor in lombard medical as we moved towards global regulatory approval and commercial launch for our lead product their experience and extensive network of worldwide contacts has been incredibly helpful to the management team and has had a very positive impact on the company at a critical time simon hubbert ceo of lombard medical public markets using our networks financial expertise and knowledge of the life science industry we identify and invest in smallcap public companies that we believe are undervalued  engaging in detailed analysis of public companies before we invest we usually remain shareholders until the investment case has played out this could be until data from a clinical trial is released a partnering deal is signed or a drug is approved we are undeterred by illogical share price drops on minor company news or periods of market weakness quite the opposite we view these as potential opportunities to invest abingworth bioequities we invest in public smallcap life science companies through our venture funds and through a separate fund abingworth bioequities abe abe is a longonly openended fund that invests globally in public life science companies abe has two complementary investment styles passive and active our passive investments which make up the majority of the fund by number are focused on well managed well capitalised companies with drug or technology assets that we believe are undervalued our active investments are vipes venture investment in public equity where the company needs new capital and restructuring these are typically larger investments led by abingworth’s venture funds for more information about abe contact kurt von emster or andrew sinclair case studies home terms of use privacy policy frc stewardship code copyright abingworth  home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal public markets using our networks financial expertise and knowledge of the life science industry we identify and invest in smallcap public companies that we believe are undervalued  engaging in detailed analysis of public companies before we invest we usually remain shareholders until the investment case has played out this could be until data from a clinical trial is released a partnering deal is signed or a drug is approved we are undeterred by illogical share price drops on minor company news or periods of market weakness quite the opposite we view these as potential opportunities to invest abingworth bioequities we invest in public smallcap life science companies through our venture funds and through a separate fund abingworth bioequities abe abe is a longonly openended fund that invests globally in public life science companies abe has two complementary investment styles passive and active our passive investments which make up the majority of the fund by number are focused on well managed well capitalised companies with drug or technology assets that we believe are undervalued our active investments are vipes venture investment in public equity where the company needs new capital and restructuring these are typically larger investments led by abingworth’s venture funds for more information about abe contact kurt von emster or andrew sinclair case studies   disclaimer privacy policy fpcs code copyright abingworth  abingworth  abingworth has a transatlantic reach signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal abingworth has a transatlantic reach with offices in the worlds key biotech centres we support entrepreneurs in both the us and europe we benefit from our transatlantic approach through a broader understanding of competitive geographies expertise in many different capital markets access to a larger pool of management talent and wider scientific networks  home terms of use privacy policy frc stewardship code copyright abingworth  home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal abingworth has a transatlantic reach with offices in the worlds key biotech centres we support entrepreneurs in both the us and europe we benefit from our transatlantic approach through a broader understanding of competitive geographies expertise in many different capital markets access to a larger pool of management talent and wider scientific networks    disclaimer privacy policy fpcs code copyright abingworth  abingworth  send us your proposal signin search  about about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio venture portfolio case studies media recent news film contact contact us send us your proposal send us your proposal abingworth partners with entrepreneurs to build successful life science companies please use the form to submit a twopage nonconfidential summary of your business plan including the products you intend to develop underlying technology and target market your competitive position the leadership team your development stage and financing needs contact information for the ceo name phone number email address subject message attach business plan home terms of use privacy policy frc stewardship code copyright abingworth  home about us about us our team transatlantic reach funds strategy our strategy venture capital clinical co‑development vipes public markets portfolio portfolio companies case studies media centre recent news archived news film contact contact us send us your proposal send us your proposal abingworth partners with entrepreneurs to build successful life science companies please use the form to submit a twopage nonconfidential summary of your business plan including the products you intend to develop underlying technology and target market your competitive position the leadership team your development stage and financing needs contact information for the ceo name phone number email address subject message attach business plan   disclaimer privacy policy fpcs code copyright abingworth  abingworth llp private company information  bloomberg july    pm et capital markets company overview of abingworth llp snapshot people company overview abingworth llp is a private equity and venture capital firm specializing in investments in all stages of development including early venture mid venture venture growth startups and latestage venture financing growth equity as well as undervalued public companies via pipe vipes venture investments in public equities the firm invests in life sciences opportunities encompassing seed stage projects technology platforms preclinical and clinical assets as well as approved and marketed products with a focus on biotherapeutics small molecules nucleic acid therapeutics vaccines speciality pharma medical devices diagnostics and lab instrumentation it also invests in platform and ena abingworth llp is a private equity and venture capital firm specializing in investments in all stages of development including early venture mid venture venture growth startups and latestage venture financing growth equity as well as undervalued public companies via pipe vipes venture investments in public equities the firm invests in life sciences opportunities encompassing seed stage projects technology platforms preclinical and clinical assets as well as approved and marketed products with a focus on biotherapeutics small molecules nucleic acid therapeutics vaccines speciality pharma medical devices diagnostics and lab instrumentation it also invests in platform and enabling technologies providers payors specialty services software and related services and biotechnology the firm invests in companies based in the united states united kingdom and continental europe the firm invests between  million and  million per investment either initially or over time the firm holds its investments for a period of three to eight years it prefers to take majority ownership it also seeks to take board seats on its portfolio companies abingworth llp was founded in  and is based in london united kingdom with additional offices in menlo park california and boston massachusetts detailed description  jermyn streetprinces houseth floorlondon  swy dnunited kingdomfounded in  phone     fax     wwwabingworthcom key executives for abingworth llp mr stephen bunting phd chairman age  mr timothy j haines bsc mba managing partner age  mr kurt von emster cpa cfa managing partner age  mr james abell chief financial officer and partner mr john heard jd partner and general counsel compensation as of fiscal year  abingworth llp key developments abingworth llp presents at bioequity europe  may  am may   abingworth llp presents at bioequity europe  may  am venue marriott rive gauche  boulevard saint jacques paris  france speakers tim haines managing partner abingworth llp presents at investment for advanced therapies summit may  am may   abingworth llp presents at investment for advanced therapies summit may  am venue cms cameron mckenna offices cannon place london united kingdom speakers genghis lloydharris partner abingworth llp presents at medtech strategist innovation summit dublin  apr  pm apr   abingworth llp presents at medtech strategist innovation summit dublin  apr  pm venue the shelbourne hotel  st stephen’s green dublin  ireland speakers timothy j haines managing partner similar private companies by industry company name region sipp plc europe i plc europe a e taylor financial services limited europe alist equity research limited europe a anthony corporate limited europe recent private companies transactions typedate target private placement july   effector therapeutics inc private placement may   gammadelta therapeutics ltd mergeracquisition april   epigenomics ag request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact abingworth llp please visit wwwabingworthcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close abingworth llp  law search advanced search take a free trial  sign in close law indepth law uk adv search  platform tools browse all sections banking bankruptcy class action competition employment energy expert analysis insurance intellectual property product liability securities rankings laws mvps glass ceiling report global  law  diversity snapshot practice group partner rankings practice groups of the year pro bono firms of the year rising stars trial aces site menu join the law team search legal jobs learn more about law read testimonials contact law sign up for our newsletters site map help abingworth llp news  case alert on abingworth llp financial » asset management » abingworth llp menu options for abingworth llp everything » news  analysis » new cases » new ptab cases » case activity » outside counsel » data on cases clients outside counsel and individual attorneys collected from active federal civil cases reflects only recently published court data not intended to be exhaustive not responsible for errors in court dockets × please assign a name to this alert save alert cancel news  may   lab services market remains ripe for private equity  investors including ampersand capital partners tekla capital management abingworth and boston community january   abingworth raises m for life sciences codevelopment life sciences investment firm abingworth said thursday that the european investment fund and others cases  no results ptab cases  no results to view all the results and drill down deeper take a free trial now try law free for seven days already a subscriber click here to login × already have access click here to login get instant access to the onestop news source for business lawyers register now get instant access to the onestop news source for business lawyers email professional email required first name last name please note a verification email will be sent to your address before you can access your trial password at least  characters required confirm password select at least one primary interest aerospace  defense appellate asset management automotive banking bankruptcy california capital markets class action commercial contracts competition consumer protection corporate cybersecurity  privacy delaware employment energy environmental financial services uk florida food  beverage government contracts health hospitality illinois immigration insurance insurance uk intellectual property international arbitration international trade law in depth legal ethics life sciences media  entertainment medical malpractice mergers  acquisitions native american new jersey new york pennsylvania private equity product liability project finance public policy real estate retail  e commerce securities sports tax technology telecommunications texas transportation trials white collar register already have access email password forgot your password remember login sign in abingworth trademark of abingworth llp serial number   trademarkia trademarks apply online attorneys services us trademark registration service international trademark registration service trademark office action response trademark statement of use trademark renewal trademark assignment trademark watch trademark cease  desist trademark comprehensive search copyright registration patent services incorporation services business page creation more services help contact us login trademark search trademark category advertising business  retail services abingworth   get free email alerts abingworth trademark information abingworth llp advertising business management business consultancy services business administration providing office functions insurance namely insurance and reinsurance claims administration and insurance risk portfolio and investment management financial affairs namely providing advice regarding venture capital financing financial consultation and analysis and investment advice and the investment of funds for others and investment and portfolio company management monetary affairs namely providing money management and investment advisory services finan advisory services relating to scientific research management of scientific research projects preparation of reports relating to scientific research provision of information relating to scientific research scientific research scientific consultancy services in the field of life sciences scientific and technological services and research and design relating thereto in the field of life sciences industrial analysis and research services in perfect for these industries advertising business  retail services insurance  financial services computer  software services  scientific services words that describe this mark advertising   business   management   business   consultancy   services   business   administration   providing   office   functions   this is a brand page for the abingworth trademark by abingworth llp  in london  swy dn write a review about a product or service associated with this abingworth trademark or contact the owner abingworth llp of the abingworth trademark by filing a request to communicate with the legal correspondent for licensing use andor questions related to the abingworth trademark on thursday june   a us federal trademark registration was filed for abingworth by abingworth llp london swy dn the uspto has given the abingworth trademark serial number of  the current federal status of this trademark filing is continued use and incontestibility accepted the correspondent listed for abingworth is maryann e licciardi of cowan liebowitz  latman pc  avenue of the americas new york ny   the abingworth trademark is filed in the category of advertising business  retail services  insurance  financial services  computer  software services  scientific services  the description provided to the uspto for abingworth is advertising business management business consultancy services business administration providing office functions word mark abingworth statusstatus date continued use and incontestibility accepted  serial number  filing date  registration number  registration date  goods and services advertising business management business consultancy services business administration providing office functions mark description not available type of mark service mark published for opposition date  last applicantowner abingworth llplondon swy dn why is this contact information displayed why is this contact information displayed close the uspto makes this data available for search by the public so that individuals can locate ownership information for intellectual property much the same way a county might make real estate property ownership information available since our website is synchronized with the uspto data we recommend making any data changes with the uspto directly our website will autoupdate when the uspto data is updated you may also contact trademarkia to make a request for the removal of your personally identifiable information or trademark data such requests must be made in writing and will be subject to verification of ownership this policy allows verified trademark owners to specify a that their identifiable information be masked or b that their trademark pages permanently deleted from trademarkiacom requests may be made directly to customerservicetrademarkiacom and every effort will be made to honor them within  hours click here for further details close mark drawing code standard character mark design search no data register type principal disclaimer not available correspondent maryann e licciardi cowan liebowitz  latman pc  avenue of the americas new york ny  use in commerce trademark  applicant has provided proof of use of this mark in commerce to uspto classification information primary class class   advertising business management business administration office functions first use anywhere not provided first use in commerce not provided primary class class   insurance financial affairs monetary affairs real estate affairs first use anywhere not provided first use in commerce not provided primary class class   scientific and technological services and research and design relating thereto industrial analysis and research services design and development of computer hardware and software first use anywhere not provided first use in commerce not provided trademarkia is the largest search engine for us trademarks each month hundreds of trademarks around the world are filed by licensed attorneys in the legalforcetrademarkia network you can register your trademark in  countries in the world through legalforce network legalforce network can help you incorporate a business around your abingworth trademark in less than  minutes trademarkia makes the process easy and convenient so start now trademarkiacom is a free search engine of publicly available government records trademarkiacom is not a law firm and does not represent owners  correspondents listed on this page trademark document retrieval  trademark  apply online  satisfaction guarantee protect your valuable brand now how it works what you get  legalforce rapc   us trademark filing from  to now  describe how your business or product is being used register your mark in  countries just   govt fees start here   top global ip attorneys  credibility and experience  all processes will be performed in a timely manner you will be informed periodically about the process keep track of this brand trademark watch services keep track of how your trademark is being used available in the united states and in more than  countries roundtheclock monitoring monthly report on potential infringement watch this trademark trademark watch services read more current trademark status  continued use and incontestibility accepted free trademark search correspondent search maryann e licciardi is a correspondent of abingworth trademark current overall rating  review what you can do start your business free logo creator add to favorites view documents free trademark search start trademark filing process protect this mark internationally custom logo design  search abingworth on popular social networks trademarkia lets you see how your personal name product name trademark name or username is being used on any of  new and popular social networks be the first to reserve your name and get help stopping others from using it  all in one place trademark oppose service you can request for extension of time to oppose this mark or oppose it now  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       status update alerts status update alerts are email updates of the latest trademark status change please make sure you provide the correct email  if you are new to legalforcetrademarkia please just enter your contact email and create a password  if you already have a legalforcetrademarkia account please enter your accounts email and password  email address please enter your email address  enter password please enter your password  please enter the value       review  rating please rate and review for abingworth abingworth is providing advertising business management business consultancy services business administration providing office functions  if you are new to legalforcetrademarkia please just enter your contact email and create a password to be associated with your review if you already have a legalforcetrademarkia account please enter your accounts email and password before posting your review  please rate        your review please enter your review  email address please enter your email address  enter password please enter your password         kurt emster abingworth llp profile  biography  bloomberg feedback kurt emster managing partner abingworth llp career history interim chairman sutrovax inc present managing partner abingworth llp present cofounder venbio llc present cofounder mpm bioequities fund present managing partner abingworth management holdings ltd present partner abingworth llp  managing partnercofounder venbio llc  managing partner venbio partners llc unknown comanager venbio select fund llc  portfolio managergen partner mpm bioequities fund  comanager franklin strategic series  franklin biotechnology discovery fund  comanager franklin global health care fund  various positions franklin templeton group  abingworth management holdings ltd unknown portfolio managerfounder franklin biotechnology discovery fund former general partner mpm capital lp former show more corporate information address phone  fax  from the web personal information education stanford university postgraduate certificate  university of california santa barbara bachelors degree awards  publications certificates chartered financial analyst cfa certified public accountant cpa memberships board memberships crispr therapeutics ag board member present kesios therapeutics ltd board member present sutrovax inc interim chairman present crispr therapeutics ltd board member present cymabay therapeutics inc board member present cytos biotechnology ag board member  kuros biosciences ag board member unknown aurinia pharmaceuticals inc board member  metabolex inc board member  facet biotechnology board member former facet biotech corp board member unknown somaxon pharmaceuticals inc board member unknown show more other memberships security analysts of san francisco member assn for investment management  research member sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view abingworth llp sc da filing concerning prto on  whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active schedule da filed by abingworth llp total shares  subject company proteon theraptc  view complete ownership history backtest filed as of date  event date  overall  ownership  reporting persons name solevoting power sharedvoting power soledispositive power shareddispositive power aggregateamount owned percentof class  abingworth llp         abingworth bioventures vi lp        view original filing on edgars raw filing contents txt   hdrsgml    accession number  conformed submission type sc da public document count  filed as of date  date as of change  group members abingworth bioventures vi lp subject company company data company conformed name proteon therapeutics inc central index key  standard industrial classification biological products no diagnostic substances  irs number  state of incorporation de fiscal year end  filing values form type sc da sec act  act sec file number  film number  business address street   west street city waltham state ma zip  business phone  mail address street   west street city waltham state ma zip  filed by company data company conformed name abingworth llp central index key  irs number  state of incorporation x fiscal year end  filing values form type sc da business address street   jermyn street city london state x zip swy dn business phone     mail address street   jermyn street city london state x zip swy dn sc da  proteondamjunhtm proteon d amendment no    united states securities and exchange commission washington dc  schedule d amendment no   under the securities exchange act of      proteon therapeutics inc name of issuer   common stock  par value per share title of class of securities   l cusip number   john heard abingworth llp princes house  jermyn street london england swy dn     name address and telephone number of person authorized to receive notices and communications   june   date of event which requires filing of this statement     if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of §§ de df or dg check the following box ☐   note schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits see § d for other parties to whom copies are to be sent   the remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page   the information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section  of the securities exchange act of  “act” or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes         cusip no  l  names of reporting persons  irs identification nos of above persons entities only   abingworth llp         check the appropriate box if a member of a group       a ☐       b ☒    sec use only  source of funds see instructions  wc see item   check if disclosure of legal proceedings is required pursuant to items d or e ☐  citizenship or place of organization  england     number of shares  sole voting power       beneficially owned by  shared voting power      each reporting person with  sole dispositive power        shared dispositive power             aggregate amount beneficially owned by each reporting person    check if the aggregate amount in row  excludes certain shares see instructions   ☐    percent of class represented by amount in row     type of reporting person see instructions pn                   as of june   the “event date” and as of the date of filing of this amendment no  to schedule d the “filing date” abingworth llp “abingworth” may be deemed to beneficially own an aggregate of  shares of common stock  par value per share the “common stock” of proteon therapeutics inc the “issuer” the number of shares of common stock reported above consists of i  shares of common stock held by abingworth bioventures vi lp “abv vi” and ii  shares of common stock issuable upon exercise of options the “options” issued to timothy haines “haines” a member of abingworth in connection with his service as a director of the issuer abingworth provides advisory services to abv vi under an agreement between haines and abingworth haines is deemed to hold the options and any shares of common stock issuable upon exercise of the options for the benefit of abv vi and must exercise the options solely upon the direction of abingworth the options are exercisable as of the event date and as of the filing date   the number of shares of common stock reported above excludes for purposes of rule d under the securities exchange act of  as amended the “exchange act” a  shares of common stock issuable upon exercise of options issued to haines not exercisable within  days from the event date or from the filing date and b  shares of series a convertible preferred stock the “series a stock” which is convertible at the option of the holder subject to the  cap into  shares of common stock at a price per share equal to  the series a stock contains a provision prohibiting conversion to the extent that upon conversion the holder together with its affiliates and any “group” members would beneficially own in excess of  of the number of shares of common stock then outstanding the “ cap”   as a result of the foregoing as of the event date and the filing date for purposes of rule d under the exchange act abingworth as the investment manager of abv vi may be deemed to beneficially own the  shares of common stock held by abv vi and the  shares of common stock issuable upon exercise of options issued to haines or an aggregate of approximately  of the shares of common stock deemed issued and outstanding the foregoing beneficial ownership percentage is based upon  shares of common stock issued and outstanding as of april   as reported by the issuer in its quarterly report on form q for the quarterly period ended march   file no  filed with the securities and exchange commission on may           cusip no  l  names of reporting persons  irs identification nos of above persons entities only   abingworth bioventures vi lp         check the appropriate box if a member of a group       a ☐       b ☒    sec use only  source of funds see instructions  wc see item   check if disclosure of legal proceedings is required pursuant to items d or e ☐  citizenship or place of organization  england     number of shares  sole voting power       beneficially owned by  shared voting power      each reporting person with  sole dispositive power        shared dispositive power            aggregate amount beneficially owned by each reporting person    check if the aggregate amount in row  excludes certain shares see instructions   ☐    percent of class represented by amount in row     type of reporting person see instructions pn                   as of june   the “event date” and as of the date of filing of this amendment no  to schedule d the “filing date” abingworth bioventures vi lp “abv vi” held an aggregate of  shares of common stock  par value per share the “common stock” of proteon therapeutics inc the “issuer” the number of shares of common stock reported above consists of i  shares of common stock held by abv vi and ii  shares of common stock issuable upon exercise of options the “options” issued to timothy haines “haines” a member of abingworth llp abingworth in connection with his service as a director of the issuer abingworth provides advisory services to abv vi under an agreement between haines and abingworth haines is deemed to hold the options and any shares of common stock issuable upon exercise of the options for the benefit of abv vi and must exercise the options solely upon the direction of abingworth the options are exercisable as of the event date and as of the filing date       the number of shares of common stock reported above excludes for purposes of rule d under the securities exchange act of  as amended the “exchange act” a  shares of common stock issuable upon exercise of options issued to haines not exercisable within  days from the event date or from the filing date and b  shares of series a convertible preferred stock the “series a stock” which is convertible at the option of the holder subject to the  cap as defined below into  shares of common stock at a price per share equal to  the series a stock contains a provision prohibiting conversion to the extent that upon conversion the holder together with its affiliates and any “group” members would beneficially own in excess of  of the number of shares of common stock then outstanding the “ cap”   as a result of the foregoing as of the event date and the filing date for purposes of rule d under the exchange act abv vi may be deemed to beneficially own the  shares of common stock held by it and the  shares of common stock issuable upon exercise of options issued to haines or an aggregate of approximately  of the shares of common stock deemed issued and outstanding the foregoing beneficial ownership percentage is based upon  shares of common stock issued and outstanding as of april   as reported by the issuer in its quarterly report on form q for the quarterly period ended march   file no  filed with the securities and exchange commission on may               explanatory note   this amendment no  this “amendment” amends and supplements the schedule d filed on behalf of i abingworth bioventures vi lp “abv vi” and ii abingworth llp an english limited liability partnership the investment manager of abv vi “abingworth” and together with abv vi the “reporting persons” with the securities and exchange commission the “sec” on october   the “schedule d” except as specifically provided herein this amendment does not modify or amend any of the information previously reported in the schedule d capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the schedule d   item    source and amount of funds or other consideration   abv vi purchased the  shares of series a convertible preferred stock the “series a stock” of proteon therapeutics inc the “issuer” at a purchase price of  per share of series a stock for a total of  the series a stock is convertible at the option of the holder into  shares of common stock  par value per share the “common stock” of the issuer at a price per share equal to  abv vi purchased the series a stock with its investment capital abingworth does not directly own any of the shares of series a stock   item    purpose of transaction item  of the schedule d is hereby amended by deleting it in its entirety and substituting the following in lieu thereof   the reporting persons acquired the securities reported herein for investment in the ordinary course of business because of their belief that the issuer represents an attractive investment based on the issuer’s business prospects and strategy the reporting persons reserve the right to acquire or cause to be acquired additional securities of the issuer to dispose of or cause to be disposed of such securities at any time or to formulate other purposes plans or proposals regarding the issuer or any of its securities to the extent deemed advisable in light of general investment and trading policies of the reporting persons market conditions or other factors each reporting person may from time to time enter into stock trading plans intended to satisfy the requirements of rule b of the securities exchange act of  as amended the “exchange act”   currently timothy haines a member investment director and partner of abingworth serves on the board of directors of the issuer the “board” mr haines was appointed to the board in may  mr haines also serves on the governance and nominating committee and the compensation committee of the board mr haines has been issued to date an aggregate of  shares of common stock issuable upon exercise of options the “options” in connection with his service as a member of the board abingworth provides advisory services to abv vi under an agreement between haines and abingworth haines is deemed to hold the options and any shares of common stock issuable upon exercise of the options for the benefit of abv vi and must exercise the options solely upon the direction of abingworth  options were exercisable as of the event date as defined below and as of the date of filing of amendment no  to the schedule d the “filing date” the  shares of common stock issuable upon exercise of options issued to haines not exercisable within  days of the event date and filing date will vest at the issuer’s next annual meeting of stockholders scheduled for june            on june   the “event date” abv vi entered into a securities purchase agreement the “purchase agreement” whereby i the issuer issued and sold to abv vi and abv vi purchased from the issuer  shares of series a stock which is convertible at the option of the holder subject to the  cap as defined below into  shares of common stock at a price per share equal to  and ii the issuer issued and sold to other purchasers  shares of series a stock which is convertible at the option of the holders into  shares of common stock at a price per share equal to  the transactions specified in clauses i and ii above are referred to herein collective as the “private placement” the series a stock contains a provision prohibiting conversion to the extent that upon conversion the holder together with its affiliates and any “group” members would beneficially own in excess of  of the number of shares of common stock then outstanding the “ cap”   in connection with the private placement the holders of a majority of the outstanding shares of series a stock will be entitled to elect one  member of the company’s board of directors the “series a director” each share of series a stock will be entitled to a preference of  per share upon liquidation of the company and thereafter will share ratably in any distributions or payments on an asconverted basis with the holders of common stock in addition if certain transactions that involve the merger or consolidation of the company an exchange or tender offer a sale of all or substantially all of the assets of the company or a reclassification of the common stock occur each of the series a stock would be convertible into the kind and amount of securities cash andor other property that the holder of a number of shares of common stock issuable upon conversion of one share of series a stock would receive in connection with such transaction however in the event any such transaction occurs at any time prior to the first date that the volumeweighted average price per share of common stock for each of the trading days during any twenty consecutive trading days ending on or at any time after the one year anniversary of the approval of the company’s biologics license application for the company’s product vonapanitase by the united states food and drug administration is greater than  of the conversion price and if the aggregate value of such securities cash andor property to which a holder of a share of series a stock would be entitled upon conversion would be less than the price per share paid for the series a stock the “stated value” then each share of series a stock shall instead be convertible into such kind of securities cash andor other property with an aggregate value equal to the stated value except as otherwise required by law or with respect to the election of one director to the company’s board of directors and approval of certain actions specified in the certificate of designation the series a stock will not have voting rights   pursuant to the registration rights agreement entered into with each investor in the private placement each investor including abv vi will be entitled to certain shelf and “piggyback” registration rights with respect to the shares of common stock issuable upon conversion of the series a stock subject to the limitations set forth in such agreement   concurrently with the execution and delivery of the purchase agreement certain stockholders of the company including abv vi each a “stockholder” representing a majority of the company’s outstanding shares of common stock entered into voting agreements each a “voting agreement” and collectively the “voting agreements” with the company pursuant to which each stockholder agreed to vote its shares of common stock in favor of those matters in connection with the private placement that require approval by the stockholders of the company pursuant to the rules of the nasdaq stock market the voting agreements terminate upon the earlier to occur of i immediately following a meeting of the company’s stockholders at which the transaction is voted upon and approved by the company’s stockholders and ii the termination of the purchase agreement at any time prior to the consummation of the closing contemplated under the purchase agreement     lastly concurrently with the execution and delivery of the purchase agreement the issuer and certain stockholders of the company including abv vi entered into a fifth amended and restated investors’ rights agreement dated as of june   the “fifth ira” pursuant to which such stockholders have agreed to certain limitations on the registration rights provided for under that certain fourth amended and restated investors’ rights agreement dated as of may   with the effectiveness of the fifth ira to be contingent upon the closing of the private placement   the above description of the purchase agreement certificate of designation registration rights agreement voting agreement and fifth ira is qualified in its entirety by reference to such documents copies of which are filed as exhibits to amendment no  to the schedule d   except as set forth herein the reporting persons do not have any plan or proposal that would relate to or result in any of the matters set forth under subsections a through j of item  of schedule d     item    interest in securities of the issuer   item  of the schedule d is hereby amended by deleting it in its entirety and substituting the following in lieu thereof   a        abv vi and abingworth as the investment manager to abv vi may be deemed to beneficially own in the aggregate  shares of common stock representing an aggregate of approximately  of the shares of common stock of the issuer deemed issued and outstanding as of the filing date the foregoing beneficial ownership percentage is based upon  shares of common stock issued and outstanding as of april   as reported by the issuer in its quarterly report on form q for the quarterly period ended march   file no  filed with the securities and exchange commission on may   the number of shares of common stock reported above excludes for purposes of rule d under the exchange act a  shares of common stock issuable upon exercise of options issued to haines not exercisable within  days from the event date or from the filing date and b  shares of series a stock which is convertible at the option of the holder subject to the  cap into  shares of common stock at a price per share equal to    b       as set forth in the cover sheets to this schedule d i abv vi has shared voting and dispositive power with respect to the  shares of common stock the  shares of common stock issuable upon exercise of options issued to haines and the  shares of series a stock which is convertible at the option of the holder subject to the  cap into  shares of common stock held by abv vi and does not have sole voting and dispositive power over any of the securities reported herein ii abingworth has shared voting and dispositive power with respect to the  shares of common stock the  shares of common stock issuable upon exercise of options issued to haines and the  shares of series a stock which is convertible at the option of the holder subject to the  cap into  shares of common stock held by abv vi and does not have sole voting and dispositive power over any of the securities reported herein       c       on june   abv vi entered into a purchase agreement whereby i the issuer issued and sold to abv vi and abv vi purchased from the issuer  shares of series a stock which is convertible at the option of the holder subject to the  cap into  shares of common stock at a price per share equal to  and ii the issuer issued and sold to other purchasers  shares of series a stock which is convertible at the option of the holders subject to the  cap into approximately  shares of common stock at a price per share equal to    except as described herein during the past sixty  days on or prior to the event date and from the event date to the filing date there were no other purchases or sales of shares of common stock or securities convertible into or exchangeable for shares of common stock by the reporting persons or any person or entity for which the reporting persons possess voting or dispositive control over the securities thereof   d       abv vi has the right to receive dividends from or proceeds from the sale of the shares of common stock beneficially owned by it the partners of abv vi have the right to participate indirectly in the receipt of dividends from or proceeds from the sale of the shares of common stock beneficially owned by it in accordance with their respective ownership interests in abv vi      item    contracts arrangements understandings or relationships with respect to securities of the issuer   item  of the schedule d is hereby amended by deleting it in its entirety and substituting the following in lieu thereof    except as otherwise set forth in this schedule d there are no contracts arrangements understandings or similar relationships existing with respect to the securities of the issuer and any of the reporting persons      item    material to be filed as exhibits   the following exhibit is incorporated into this schedule d      exhibit  form of certificate of designation of preferences rights and limitations of series a convertible preferred stock incorporated by reference to exhibit  to the form k filed by the issuer with the securities and exchange commission on june   exhibit  form of registration rights agreement incorporated by reference to exhibit  to the form k filed by the issuer with the securities and exchange commission on june            exhibit  voting agreement dated june   by and between proteon therapeutics inc and abingworth bioventures vi lp incorporated by reference to exhibit  to the form k filed by the issuer with the securities and exchange commission on june   exhibit  fifth amended and restated investors’ rights agreement dated june   by and among proteon therapeutics inc and the stockholders party thereto incorporated by reference to exhibit  to the form k filed by the issuer with the securities and exchange commission on june   exhibit  securities purchase agreement dated june   by and among proteon therapeutics inc and the investors party thereto incorporated by reference to exhibit  to the form k filed by the issuer with the securities and exchange commission on june                 signature after reasonable inquiry and to the best of my knowledge and belief i certify that the information set forth in this statement is true complete and correct   dated  june       abingworth bioventures vi lp   by abingworth llp its manager     by s john heard                                                name  john heard      title  authorized signatory     abingworth llp     by  s john heard                                         name  john heard title  authorized signatory           attention intentional misstatements or omissions of fact constitute federal criminal violations see  usc      elevate your investments try it for free microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft abingworth llp  netfind content results aol search skip over navigation search the web web web content form an llp online  complete our simple questionnaire ad · wwwlegalzoomcom​llp complete our simple questionnaire safeguard your personal assets form an llp form an llc stepbystep guide corporation abingworth company abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london more go to encyclopedia results from the wowcom content network wilson therapeutics  wowcom wwwwowcomwikiwilsontherapeutics wilson therapeutics is a biopharmaceutical company  abingworth llp mvm life science partners llp and neomed management as amarin corporation  wowcom wwwwowcomwikiamarincorporation amarin corporation is a biopharmaceutical company founded in  and headquartered in bedminster  phd partner at abingworth llp lars ekman  form an llp online  complete our simple questionnaire ad · wwwlegalzoomcom​llp complete our simple questionnaire safeguard your personal assets form an llp form an llc stepbystep guide corporation searches related toabingworth llp abingworth bioventures abingworth ventures abingworth management abingworth venture capital abingworth management inc atlas bioventures joe anderson abingworth abell venture fund related searches abingworth bioventures abingworth ventures abingworth management abingworth venture capital abingworth management inc atlas bioventures joe anderson abingworth abell venture fund search the web  aol inc all rights reservedprivacy   terms of use   preferences   contact us   powered by bing™ wowcom  part of the aol search network abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view creative commons — attributionsharealike  unported — cc bysa  skip to content menu help us build a vibrant collaborative global commons donate now creative commons creative commons license deed attributionsharealike  unported cc bysa  this is a humanreadable summary of and not a substitute for the license disclaimer you are free to share — copy and redistribute the material in any medium or format adapt — remix transform and build upon the material for any purpose even commercially the licensor cannot revoke these freedoms as long as you follow the license terms under the following terms attribution — you must give appropriate credit provide a link to the license and indicate if changes were made you may do so in any reasonable manner but not in any way that suggests the licensor endorses you or your use attribute this work sharealike — if you remix transform or build upon the material you must distribute your contributions under the same license as the original no additional restrictions — you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits notices you do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation no warranties are given the license may not give you all of the permissions necessary for your intended use for example other rights such as publicity privacy or moral rights may limit how you use the material learn more about cc licensing or use the license for your own material this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work make a donation this page is available in the following languages castellano castellano españa català dansk deutsch english esperanto français galego hrvatski indonesia italiano latviski lietuvių melayu nederlands norsk polski português português br română slovenščina suomeksi svenska türkçe íslenska česky ελληνικά беларуская русский українська العربية پارسی     한국어 this content is freely available under simple legal terms because of creative commons a nonprofit that survives on donations if you love this content and love that its free for everyone please consider a donation to support our work when you share everyone wins contribute today to creative commons     disclaimer this deed highlights only some of the key features and terms of the actual license it is not a license and has no legal value you should carefully review all of the terms and conditions of the actual license before using the licensed material creative commons is not a law firm and does not provide legal services distributing displaying or linking to this deed or the license that it summarizes does not create a lawyerclient or any other relationship what does attribute this work mean the page you came from contained embedded licensing metadata including how the creator wishes to be attributed for reuse you can use the html here to cite the work doing so will also include metadata on your page so that others can find the original work as well the applicable mediation rules will be designated in the copyright notice published with the work or if none then in the request for mediation unless otherwise designated in a copyright notice attached to the work the uncitral arbitration rules apply to any arbitration more info if supplied you must provide the name of the creator and attribution parties a copyright notice a license notice a disclaimer notice and a link to the material cc licenses prior to version  also require you to provide the title of the material if supplied and may have other slight differences more info in  you must indicate if you modified the material and retain an indication of previous modifications in  and earlier license versions the indication of changes is only required if you create a derivative marking guide more info you may also use a license listed as compatible at httpscreativecommonsorgcompatiblelicenses more info a commercial use is one primarily intended for commercial advantage or monetary compensation more info merely changing the format never creates a derivative more info the license prohibits application of effective technological measures defined with reference to article  of the wipo copyright treaty more info the rights of users under exceptions and limitations such as fair use and fair dealing are not affected by the cc licenses more info you may need to get additional permissions before using the material as you intend more info abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view abingworth company  wikipedia abingworth company from wikipedia the free encyclopedia jump to navigation search abingworth llp formerly abingworth management ltd is a londonbased independent venture capital firm and registered investment advisory firm founded in  by a pair of london stockbrokers peter dicks and anthony montagu abingworth had initially sought to extend its investments into the biotechnology industry in the late s and has subsequently been investing in life science and healthcare services companies since at least  and had expanded to include information technology firm investments by  contents  offices  investments  corporate details  references  external links officesedit in addition to its base in london the company had a second office in palo alto california as of citation needed by  the palo alto office had been replaced by an office in menlo park and an additional offices had been established in boston massachusetts and cambridge united kingdom investmentsedit the companys investment strategy involves the establishment of funds with particular investment targets in mind for instance the bioventures vi fund was closed in march  having accrued  million reportedly exceeding the target for the fund a key element in the firms investment strategy is the exit which signifies the acquisition of or initial public offering by a company in which the firm has invested prior to  abingworth had made investments considered by  to have been successful in apple and silicon graphics the firm created its biotech investment arm in  among the first investments was in immunology ltd which was later renamed to cantab pharmaceuticals in  the company joined several others in providing funding for oxagen in the early s the firm invested in and saw forward to initial public offering a number of firms including dicerna pharmaceuticals and clovis oncology the firm has also provided funding to support the acquisition of algeta by bayer and avila therapeutics by celgene in the algeta case this was the very first of the firms venture investments in public equities dating to february  in  the firm realized an exit from investment in syntaxin ltd when it was acquired by ipsen sa in  the firm invested in effector therapeutics it also in january  set up avillion group partners a clinical phase iii codevelopment accelerator with massachusettsbased clarus ventures following from this avillion partnered with pfizer on a label expansion effort for bosulif in  the firm invested in two ophthalmic companies avedro and gensight biologics corporate detailsedit as of update abingworth had less than  employeescitation needed by  the firm had at least  employees as of update there were two managing partners timothy j haines and kurt von emster james abell has held the post of chief financial officer since at least  special partner david leathers joined the firm in  having left rothchild the company also has a board of directors which consisted of two members in  stephen bunting and theodore clark bunting had been a managing partner from  to at least  having joined abingworth in  after leaving rothchild with leathers by  bunting had been involved in the establishment each of the ten at that time of the companys life science investment funds as of update the company managed  million across several funds and had provided capital to sixty life science companiescitation needed more than a decade later the managed value of one of the firms ten funds was  million referencesedit  a b c d e f abingworth llp private company information bloomberg retrieved  november    abingworth llp top holdings whale wisdom retrieved  november    a b c d e f g h owen geoffrey hopkins michael m  science the state and the city britains struggle to succeed in biotechnology oxford university press isbn  – via google books   a b abingworth new england venture capital association archived from the original on  april  retrieved  november    a b c d e f g h i j abingworth closes on its th life sci fund  an upsized m bioworld today  march  retrieved  november  – via highbeam research   a b c d e garde damian  february  with m in the bank vc abingworth hunts for a few promising biotechs fiercebiotech retrieved  november    bray chad bayer to acquire drug maker algeta in  billion deal dealbook retrieved    hansen stephen  february  how healthcap abingworth apply lessons from successful algeta investment biocentury retrieved  november  subscription required help   algeta raises m in a placing sciencebusiness  february  retrieved  november   external linksedit company website wwwabingworthcom company linkedin account wwwlinkedincomcompanyabingworth company crunchbase record wwwcrunchbasecomorganizationabingworthmanagemententity retrieved from httpsenwikipediaorgwindexphptitleabingworthcompanyoldid categories companies based in london establishments in the united kingdomventure capital firms of the united kingdomhidden categories pages containing links to subscriptiononly contentall articles with unsourced statementsarticles with unsourced statements from december articles containing potentially dated statements from all articles containing potentially dated statementsarticles containing potentially dated statements from  navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  may  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view